PATENT CLAIM ANALYSIS

Application Number: 15973000
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-09
Patent Classification: ["514", "012000"]

Abstract:
The present invention provides a newly identified B7 receptor, zB7R1 that functions as lymphocyte inhibitory receptor, which is a PD-1-like molecule and is expressed on T cells. The present invention also provides the discovery of zB7R1's ability to bind to CD155. Methods and compositions for modulating zB7R1-mediated negative signaling and interfering with the interaction of its counter-receptor for therapeutic, diagnostic and research purposes are also provided.

Claim (Index 7):
A pharmaceutical formulation comprising:\n a) agonist antibody or antibody fragment according to  claim 1 ; and b) a pharmaceutically acceptable vehicle.

Metadata:
- Claim Count in Document: 13.0
- Percentile: 93.0
- Lexical Diversity: 1.37736
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15611134', '15069065', '14602007', '12246214', '14893463']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7309240763900229
- 35 USC 102 Novelty (BERT): 0.5318233688831536
- Combined Prediction Score: 0.7110140056393359
- Mean Citation Score: 275.49808199999995
- Max Citation Score: 330.4095200000001
- Similarity Product: 216.8344379186154

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test